Antoinette Lemoine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Antoinette Lemoine has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Azoulay
Centre Hepato-biliaire, AP-HP Hopital Paul Brousse, Villejuif/FRANCE
11 shared publications - B. Debuire
Service de Biochimie et Biologie moléculaire‐UPRES‐EA 1596
10 shared publications H Bismuth
6 shared publicationsJ M Gries
4 shared publications- Raphaël Saffroy
Department of Biochemistry and Oncogenetic Paul Brousse Hospital Villejuif France
4 shared publications Alain Barrier
Inserm 602, Service de Biochimie et Biologie Moléculaire, Hôpital Universitaire Paul Brousse, Université Paris XI, Villejuif Cedex, France
3 shared publications
Latest Publications
- Open Access
- 17 August 2011
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 46 (Supplement) , i20-i21
S22 * YOUNG RESEARCHER SYMPOSIUM II: PATHOGENETIC MECHANISMS OF ALCOHOLIC ASSOCIATED ORGAN INJURY * S22.1 * IRON METABOLISM IN PATIENTS WITH ALD
Background. Alcoholic liver disease (ALD) is the major liver disease in the developed world that is characterized by pathological hepatic iron deposits. This non-HFE-related iron overload is considered a key mechanism of rapid disease progression towards liver cirrhosis and hepatocellular carcinoma. We here performed a systematic histological, protein and mRNA expression analysis on liver biopsies from patients with well-characterized ALD. Methods. A total of 100 patients with histologically confirmed ALD who were admitted for alcohol withdrawal were included. Clinical parameters, liver biopsies and serum iron parameters were collected. Routine histology and iron content were assessed by H&E and Prussian Blue staining, respectively. We then selected 30 liver biopsies (10 without and 20 with iron overload) for RNA isolation, reverse transcription and quantitative real-time PCR analysis for iron metabolism genes (among them hepcidin, transferrin receptor 1, ferroportin, transferrin, ferritin light and heavy chain, HO-1). In addition, liver sections were stained immunohistochemically for ferritin, ferroportin, transferrin receptor 1 and 2 and HO-1. Results. In our cohort, 50% of patients had iron overload in liver biopsy. Iron overload was mild to moderate partly found in hepatocytes and macrophages. Although serum ferritin rapidly decreases during alcohol detoxification, the initial serum–ferritin concentration showed a significant difference between those patients with and without iron overload (P = 0.02). Despite the difference in liver iron content and serum-ferritin among the two groups of ALD patients, there was no significant regulation in iron metabolism-associated genes at the RNA level. Immunohistochemistry revealed distinct and individual staining patterns for ferritin, ferroportin, TfR1 and TfR2. The intensity, however, did not correlate with Prussian Blue staining. Conclusion. Serum-ferritin is an indicator of iron overload in ALD despite its rapid decrease during alcohol withdrawal. However, absolute and spatial expression of key iron-related proteins is not correlated to iron deposits in the form of hemosiderin or ferritin.
- 17 August 2011
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 46 (Supplement) , i20-i21
Open AccessS22 * YOUNG RESEARCHER SYMPOSIUM II: PATHOGENETIC MECHANISMS OF ALCOHOLIC ASSOCIATED ORGAN INJURY * S22.1 * IRON METABOLISM IN PATIENTS WITH ALD
Background. Alcoholic liver disease (ALD) is the major liver disease in the developed world that is characterized by pathological hepatic iron deposits. This non-HFE-related iron overload is considered a key mechanism of rapid disease progression towards liver cirrhosis and hepatocellular carcinoma. We here performed a systematic histological, protein and mRNA expression analysis on liver biopsies from patients with well-characterized ALD. Methods. A total of 100 patients with histologically confirmed ALD who were admitted for alcohol withdrawal were included. Clinical parameters, liver biopsies and serum iron parameters were collected. Routine histology and iron content were assessed by H&E and Prussian Blue staining, respectively. We then selected 30 liver biopsies (10 without and 20 with iron overload) for RNA isolation, reverse transcription and quantitative real-time PCR analysis for iron metabolism genes (among them hepcidin, transferrin receptor 1, ferroportin, transferrin, ferritin light and heavy chain, HO-1). In addition, liver sections were stained immunohistochemically for ferritin, ferroportin, transferrin receptor 1 and 2 and HO-1. Results. In our cohort, 50% of patients had iron overload in liver biopsy. Iron overload was mild to moderate partly found in hepatocytes and macrophages. Although serum ferritin rapidly decreases during alcohol detoxification, the initial serum–ferritin concentration showed a significant difference between those patients with and without iron overload (P = 0.02). Despite the difference in liver iron content and serum-ferritin among the two groups of ALD patients, there was no significant regulation in iron metabolism-associated genes at the RNA level. Immunohistochemistry revealed distinct and individual staining patterns for ferritin, ferroportin, TfR1 and TfR2. The intensity, however, did not correlate with Prussian Blue staining. Conclusion. Serum-ferritin is an indicator of iron overload in ALD despite its rapid decrease during alcohol withdrawal. However, absolute and spatial expression of key iron-related proteins is not correlated to iron deposits in the form of hemosiderin or ferritin.
- 1 February 2011
- Published by INIST-CNRS in Atlas of Genetics and Cytogenetics in Oncology and Haematology
- No. 1
Mechanisms of hepatocarcinogenesis
- 1 February 2011
- Published by INIST-CNRS in Atlas of Genetics and Cytogenetics in Oncology and Haematology
- No. 1
Mechanisms of hepatocarcinogenesis
- Open Access
- 1 February 2011
- Published by INIST-CNRS in Atlas of Genetics and Cytogenetics in Oncology and Haematology
- No. 2
WFDC1 (WAP four-disulfide core domain 1)
- 1 February 2011
- Published by INIST-CNRS in Atlas of Genetics and Cytogenetics in Oncology and Haematology
- No. 2
Open AccessWFDC1 (WAP four-disulfide core domain 1)
- Open Access
- 1 February 2011
- Published by INIST-CNRS in Atlas of Genetics and Cytogenetics in Oncology and Haematology
- No. 4
SMAD4 (mothers against decapentaplegic homolog 4 (Drosophila))
- 1 February 2011
- Published by INIST-CNRS in Atlas of Genetics and Cytogenetics in Oncology and Haematology
- No. 4
Open AccessSMAD4 (mothers against decapentaplegic homolog 4 (Drosophila))
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 4072
Tumor marker kinetics: Better than imaging to assess response to chemotherapy?
4072 Background: As significance of carcinoembryonic antigen (CEA) and carbohydrate antigen19.9 (CA19.9) kinetics during preoperative chemotherapy for colorectal liver metastases (CLM) is still unknown, we explored the correlation between biological and radiological response on chemotherapy, and their comparative impact on outcome. Methods: All patients resected for CLM at our hospital between 1990 and 2004 who met the following criteria were included in the study: 1) preoperative chemotherapy, 2) complete resection of CLM, 3) no extrahepatic disease, 4) elevated tumor marker values. A 20% change of tumor marker levels was used to define biological response and progression. Correlation between biological and radiological response at CT-scan (RECIST-criteria), and their impact on overall (OS) and progression-free survival (PFS) were determined. A multivariate analysis was performed for OS and PFS. Results: A total of 119 patients fulfilled the inclusion criteria. From 94 patients with response or stabilization and 19 with progression at CT-scan, 88 (94%) and 18 (95%), respectively, had similar biological evolution for CEA. From 57 patients with response or stabilization and 11 with progression at CT-scan, 52 (91%) and 7 (64%) had similar biological evolution for CA19.9. Prognostic impact of biological and radiological response is shown in the table. Radiological response independently predicted OS. Progression of CA19.9, but not radiological response, was an independent predictor of PFS. Conclusions: In patients with CLM and elevated tumor markers, biological response is as accurate as CT-imaging to assess ‘clinical’ response. CA19.9 kinetics have even a better prognostic value than radiological response with regards to PFS. Prognostic impact of biological and radiological response Prognostic impact of biological and radiological response No. of patients 5-year overall survival (%) P 5-year progression- free survival (%) P Radiological response Response or stabilization 100 29 0.09 11 0.02 Progression 19 7 0 Biological response - CEA Response or stabilization 89 28 0.36 10 0.07 Progression 24 14 0 Biological response - CA19.9 Response or stabilization 56 33 0.002 13 0.01 Progression 12 0 0 No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 4072
Tumor marker kinetics: Better than imaging to assess response to chemotherapy?
4072 Background: As significance of carcinoembryonic antigen (CEA) and carbohydrate antigen19.9 (CA19.9) kinetics during preoperative chemotherapy for colorectal liver metastases (CLM) is still unknown, we explored the correlation between biological and radiological response on chemotherapy, and their comparative impact on outcome. Methods: All patients resected for CLM at our hospital between 1990 and 2004 who met the following criteria were included in the study: 1) preoperative chemotherapy, 2) complete resection of CLM, 3) no extrahepatic disease, 4) elevated tumor marker values. A 20% change of tumor marker levels was used to define biological response and progression. Correlation between biological and radiological response at CT-scan (RECIST-criteria), and their impact on overall (OS) and progression-free survival (PFS) were determined. A multivariate analysis was performed for OS and PFS. Results: A total of 119 patients fulfilled the inclusion criteria. From 94 patients with response or stabilization and 19 with progression at CT-scan, 88 (94%) and 18 (95%), respectively, had similar biological evolution for CEA. From 57 patients with response or stabilization and 11 with progression at CT-scan, 52 (91%) and 7 (64%) had similar biological evolution for CA19.9. Prognostic impact of biological and radiological response is shown in the table. Radiological response independently predicted OS. Progression of CA19.9, but not radiological response, was an independent predictor of PFS. Conclusions: In patients with CLM and elevated tumor markers, biological response is as accurate as CT-imaging to assess ‘clinical’ response. CA19.9 kinetics have even a better prognostic value than radiological response with regards to PFS. Prognostic impact of biological and radiological response Prognostic impact of biological and radiological response No. of patients 5-year overall survival (%) P 5-year progression- free survival (%) P Radiological response Response or stabilization 100 29 0.09 11 0.02 Progression 19 7 0 Biological response - CEA Response or stabilization 89 28 0.36 10 0.07 Progression 24 14 0 Biological response - CA19.9 Response or stabilization 56 33 0.002 13 0.01 Progression 12 0 0 No significant financial relationships to disclose.
- 9 October 2006
- Published by Springer Nature in Oncogene
- Vol. 26 (18) , 2642-2648
Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling
We have assessed the possibility to build a prognosis predictor (PP), based on non-neoplastic mucosa microarray gene expression measures, for stage II colon cancer patients. Non-neoplastic colonic mucosa mRNA samples from 24 patients (10 with a metachronous metastasis, 14 with no recurrence) were profiled using the Affymetrix HGU133A GeneChip. Patients were repeatedly and randomly divided into 1000 training sets (TSs) of size 16 and validation sets (VS) of size 8. For each TS/VS split, a 70-gene PP, identified on the TS by selecting the 70 most differentially expressed genes and applying diagonal linear discriminant analysis, was used to predict the prognoses of VS patients. Mean prognosis prediction performances of the 70-gene PP were 81.8% for accuracy, 73.0% for sensitivity and 87.1% for specificity. Informative genes suggested branching signal-transduction pathways with possible extensive networks between individual pathways. They also included genes coding for proteins involved in immune surveillance. In conclusion, our study suggests that one can build an accurate PP for stage II colon cancer patients, based on non-neoplastic mucosa microarray gene expression measures.
- 9 October 2006
- Published by Springer Nature in Oncogene
- Vol. 26 (18) , 2642-2648
Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling
We have assessed the possibility to build a prognosis predictor (PP), based on non-neoplastic mucosa microarray gene expression measures, for stage II colon cancer patients. Non-neoplastic colonic mucosa mRNA samples from 24 patients (10 with a metachronous metastasis, 14 with no recurrence) were profiled using the Affymetrix HGU133A GeneChip. Patients were repeatedly and randomly divided into 1000 training sets (TSs) of size 16 and validation sets (VS) of size 8. For each TS/VS split, a 70-gene PP, identified on the TS by selecting the 70 most differentially expressed genes and applying diagonal linear discriminant analysis, was used to predict the prognoses of VS patients. Mean prognosis prediction performances of the 70-gene PP were 81.8% for accuracy, 73.0% for sensitivity and 87.1% for specificity. Informative genes suggested branching signal-transduction pathways with possible extensive networks between individual pathways. They also included genes coding for proteins involved in immune surveillance. In conclusion, our study suggests that one can build an accurate PP for stage II colon cancer patients, based on non-neoplastic mucosa microarray gene expression measures.
- 20 February 2006
- Published by Springer Nature in Oncogene
- Vol. 25 (29) , 4067-4075
Fate and characterization of circulating tumor cells in a NOD/SCID mouse model of human hepatocellular carcinoma
There is much debate about the way in which epithelial tumors metastasize. It has been proposed that the bone marrow (BM) acts as a tumor cell reservoir. We injected human hepatocellular carcinoma (HCC) cells (Mahlavu cell line) into the livers, circulation or BM of NOD/SCID mice and circulating tumor cells were quantified. When injected under the Glisson capsule, a primary tumor developed and continuously yielded circulating tumor cells. Liver tumor removal led to a very low level of Mahlavu cells both in blood and BM 30 days later. When Mahlavu cells (cultured or from BM of primary mice femurs) were intravenously injected into mice, the number of cells in the bloodstream (BS) steadily decreased, whereas the BM was not significantly colonized. When Mahlavu cells were directly injected into one femur, the controlateral femur was not colonized. Microscopic analysis and a sensitive PCR assay (<1 Mahlavu cell/nuclear cells) both failed to detect human tumor cells in other organs regardless of injection route. In conclusion, our model strongly supports the hypothesis that HCCs continuously release cells into the BS. However, in sharp contrast with the current hypothesis, the BM is not specifically colonized by tumor cells but could store them at a very low level.
- 20 February 2006
- Published by Springer Nature in Oncogene
- Vol. 25 (29) , 4067-4075
Fate and characterization of circulating tumor cells in a NOD/SCID mouse model of human hepatocellular carcinoma
There is much debate about the way in which epithelial tumors metastasize. It has been proposed that the bone marrow (BM) acts as a tumor cell reservoir. We injected human hepatocellular carcinoma (HCC) cells (Mahlavu cell line) into the livers, circulation or BM of NOD/SCID mice and circulating tumor cells were quantified. When injected under the Glisson capsule, a primary tumor developed and continuously yielded circulating tumor cells. Liver tumor removal led to a very low level of Mahlavu cells both in blood and BM 30 days later. When Mahlavu cells (cultured or from BM of primary mice femurs) were intravenously injected into mice, the number of cells in the bloodstream (BS) steadily decreased, whereas the BM was not significantly colonized. When Mahlavu cells were directly injected into one femur, the controlateral femur was not colonized. Microscopic analysis and a sensitive PCR assay (<1 Mahlavu cell/nuclear cells) both failed to detect human tumor cells in other organs regardless of injection route. In conclusion, our model strongly supports the hypothesis that HCCs continuously release cells into the BS. However, in sharp contrast with the current hypothesis, the BM is not specifically colonized by tumor cells but could store them at a very low level.
- 1 February 2006
- Published by Elsevier in Laboratory Investigation
- Vol. 86 (2) , 154-165
Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray
- 1 February 2006
- Published by Elsevier in Laboratory Investigation
- Vol. 86 (2) , 154-165
Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray
- Open Access
- 1 October 2005
- Published by Wiley in The FASEB Journal
- Vol. 19 (12) , 1617-1626
Ischemic preconditioning modulates the expression of several genes, leading to the overproduction of IL‐1Ra, iNOS, and Bcl‐2 in a human model of liver ischemia‐reperfusion
Ischemia triggers an inflammatory response that precipitates cell death during reperfusion. Several studies have shown that tissues are protected by ischemic preconditioning (IP) consisting of 10 min of ischemia followed by 10 min of reperfusion just before ischemia. The molecular basis of this protective effect is poorly understood. We used cDNA arrays (20K) to compare global gene expression in liver biopsies from living human liver donors who underwent IP ( n =7) or not ( n =7) just before liver devascularization. Microarray data were analyzed using paired t test with a type I error rate fixed at α = 2.5 10 6 (Bonferroni correction). We found that 60 genes were differentially expressed (36 over‐ and 24 underexpressed in preconditioning group). After IP, the most significantly overexpressed gene was IL‐1Ra . This was confirmed by immunoblotting. Differentially expressed were genes involved in apoptosis ( NOD2, ephrin‐A1 , and calpain ) and in the carbohydrate metabolism. A significant increase in the amount of the anti‐apoptotic protein Bcl‐2 in preconditioned livers but no change in the cleavage of procaspase‐3, ‐8, and ‐9 was observed. We also observed an increase in the amount in the inducible nitric oxide synthase. Therefore, the benefits of IP may be associated with the overproduction of IL‐1Ra, Bcl‐2, and NO countering the proinflammatory and proapoptotic effects generated during ischemia‐reperfusion. AlainBarrier NataliaOlaya FranckChiappini FrançoisRoser OlivierScatton CédricArtus BrigitteFranc SandrineDudoit AntoineFlahault BrigitteDebuire DanielAzoulay AntoinetteLemoine Ischemic preconditioning modulates the expression of several genes, leading to the overproduction of IL‐1Ra, iNOS, and Bcl‐2 in a human model of liver ischemia‐reperfusion. FASEB J. 19, 1617–1626 (2005)
- 1 October 2005
- Published by Wiley in The FASEB Journal
- Vol. 19 (12) , 1617-1626
Open AccessIschemic preconditioning modulates the expression of several genes, leading to the overproduction of IL‐1Ra, iNOS, and Bcl‐2 in a human model of liver ischemia‐reperfusion
Ischemia triggers an inflammatory response that precipitates cell death during reperfusion. Several studies have shown that tissues are protected by ischemic preconditioning (IP) consisting of 10 min of ischemia followed by 10 min of reperfusion just before ischemia. The molecular basis of this protective effect is poorly understood. We used cDNA arrays (20K) to compare global gene expression in liver biopsies from living human liver donors who underwent IP ( n =7) or not ( n =7) just before liver devascularization. Microarray data were analyzed using paired t test with a type I error rate fixed at α = 2.5 10 6 (Bonferroni correction). We found that 60 genes were differentially expressed (36 over‐ and 24 underexpressed in preconditioning group). After IP, the most significantly overexpressed gene was IL‐1Ra . This was confirmed by immunoblotting. Differentially expressed were genes involved in apoptosis ( NOD2, ephrin‐A1 , and calpain ) and in the carbohydrate metabolism. A significant increase in the amount of the anti‐apoptotic protein Bcl‐2 in preconditioned livers but no change in the cleavage of procaspase‐3, ‐8, and ‐9 was observed. We also observed an increase in the amount in the inducible nitric oxide synthase. Therefore, the benefits of IP may be associated with the overproduction of IL‐1Ra, Bcl‐2, and NO countering the proinflammatory and proapoptotic effects generated during ischemia‐reperfusion. AlainBarrier NataliaOlaya FranckChiappini FrançoisRoser OlivierScatton CédricArtus BrigitteFranc SandrineDudoit AntoineFlahault BrigitteDebuire DanielAzoulay AntoinetteLemoine Ischemic preconditioning modulates the expression of several genes, leading to the overproduction of IL‐1Ra, iNOS, and Bcl‐2 in a human model of liver ischemia‐reperfusion. FASEB J. 19, 1617–1626 (2005)
- 26 November 2004
- Vol. 62 (6) , 649-56
[Molecular biology and hepatocellular carcinoma: current status and future prospects].
Hepatocellular carcinoma (HCC) is among the fifth most common cancers worldwide. Its incidence is still rising in part because of the high level of hepatitis C virus infection. Tumor markers currently used such as serum alpha-foetoprotein are not sufficient for diagnosis of the tumor and satisfying follow-up of the patients. Mechanisms of hepatocarcinogenesis ar not completely understood although several altered genes have been described in HCC. The genetic changes involved can be divided in at least 4 different pathways, each pathway contributing to a limited number of tumors. These are: 1) the p53 pathway involved in response to DNA damage, 2) the retinoblastoma pathway involved in the control of the cell cycle, 3) the transforming growth factor-beta (TGF-beta) pathway involved in growth inhibition, and 4) the Wnt pathway involved in cell-cell adhesion and signal transduction. Alterations of the epigenetic regulation of gene expression have also been described. Evolution of molecular biology methods tends to the development of more global genomic approaches; microsatellite instability analysis, chromosomal instability analysis or gene expression profile analysis have been used to investigate HCC. Finally, attempts to develop molecular biomarkers based on peripheral blood analysis more easily accessible in clinical routine patients have also been developed.
- 26 November 2004
- Vol. 62 (6) , 649-56
[Molecular biology and hepatocellular carcinoma: current status and future prospects].
Hepatocellular carcinoma (HCC) is among the fifth most common cancers worldwide. Its incidence is still rising in part because of the high level of hepatitis C virus infection. Tumor markers currently used such as serum alpha-foetoprotein are not sufficient for diagnosis of the tumor and satisfying follow-up of the patients. Mechanisms of hepatocarcinogenesis ar not completely understood although several altered genes have been described in HCC. The genetic changes involved can be divided in at least 4 different pathways, each pathway contributing to a limited number of tumors. These are: 1) the p53 pathway involved in response to DNA damage, 2) the retinoblastoma pathway involved in the control of the cell cycle, 3) the transforming growth factor-beta (TGF-beta) pathway involved in growth inhibition, and 4) the Wnt pathway involved in cell-cell adhesion and signal transduction. Alterations of the epigenetic regulation of gene expression have also been described. Evolution of molecular biology methods tends to the development of more global genomic approaches; microsatellite instability analysis, chromosomal instability analysis or gene expression profile analysis have been used to investigate HCC. Finally, attempts to develop molecular biomarkers based on peripheral blood analysis more easily accessible in clinical routine patients have also been developed.